Business Wire

C-LECTA

Share
c-LEcta exceeds EUR 10 million in revenue with significantly higher EBITDA

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, managed to successfully continue its growth in the fiscal year 2020 despite a challenging year overall. Revenue increased to EUR 10.4 million, while EBITDA rose sharply to EUR 2.0 million. The continued growth of the product business was an important factor in the continued growth of revenue. The good development in the first quarter of 2021 allows the management to look ahead to the current year with optimism.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005102/en/

c-LEcta managed to grow strongly once again in 2020. Despite a generally challenging economic environment, revenue in the past fiscal year rose by 14% to EUR 10.4 million. Having reached break-even earlier than planned in 2019, EBITDA rose more strongly than expected from EUR 0.2 million in 2019 to EUR 2.0 million in 2020, with the company’s total operating performance growing by 23% to EUR 11.8 million (2019: EUR 9.6 million).

In this setting, c-Lecta’s product business again proved to be a growth driver. Product revenue increased from EUR 7.2 million in 2019 to EUR 9.1 million in 2020, which represents an increase of 27%. Additional revenue totaling EUR 1.2 million can be attributed to the project business and licenses. This development once again confirms the strategic focus on the production and marketing of the company’s own products. DENARASE was the biggest growth driver in 2020. This enzyme is used in the production of vector-based vaccines, but is also put to use successfully in the future markets of gene and cell therapy. In addition, 2020 saw the launch of the DENARASE ELISA kit, which can be used to determine DENARASE quantities in process solutions. Demand significantly exceeded expectations at the start of sales. These synergy effects are also due to the improved product properties. This development demonstrates the economic potential of product families that meaningfully complement the company’s current products.

“The results really speak for themselves – we continued to show a good growth rate in the pandemic year. Our customers are also feeling the uncertainties and some held back on investments in 2020 – nevertheless, we were able to continue on our course. The revenue mix is shifting further towards products in line with our strategy. This also has an impact on the EBITDA margin, which is generally somewhat stronger in the product business than in the project business,” commented Thomas Pfaadt, CFO of c-LEcta.

c-LEcta is relying on the product business as a basis for its growth in the future, as well. Accordingly, the product portfolio is to be further expanded in order to seize additional opportunities in the future. The next product launch is already scheduled for the second half of the year. “The product business has become a real success story for us, that needs to be emphasized quite clearly. We continue to work closely with partners on joint development projects with the goal of successfully marketing our new products together. At the same time, we are investing extensively in our own product development programs. An increasingly diversified product portfolio also allows us to balance risks and address multiple target markets, both geographically and across different industries ,” commented Marc Struhalla, founder and CEO of c-LEcta.

c-LEcta is already globally positioned, approx. 95% of the company’s revenue is now generated abroad. In total, c-LEcta now serves over 200 customers in more than 40 countries. The company has concluded supply contracts for enzyme products with many customers in the pharmaceutical sector, and many customers have certified c-LEcta as their supplier. This allows the company to establish long-term customer relationships in future areas such as gene and cell therapy. Besides Europe, North America and Asia in particular play important roles.

Despite the current situation with the coronavirus and the related macroeconomic risks, the management is optimistic for the future and expects strong growth momentum in terms of both revenue and EBITDA in the current fiscal year as well. c-LEcta expects further growth to be based on both the current product portfolio and future products from its own pipeline. The increasing scaling of the product portfolio is expected to result in significant additional revenue growth as well. c-LEcta is also on a growth course in terms of its personnel. The number of employees rose by 23% in the past year and currently stands at 103; the number of employees is expected to continue to increase significantly through the end of 2021.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 100 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release

MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi

Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi

$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release

MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered

Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release

With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor

With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release

Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye